MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

hyperglycemia

  • Home
  • hyperglycemia
Timing Matters: Early Insulin Therapy Reduces Mortality in ICU Patients with Moderate Hyperglycemia
Posted inCritical Care Diabetes & Endocrinology news

Timing Matters: Early Insulin Therapy Reduces Mortality in ICU Patients with Moderate Hyperglycemia

Posted by By MedXY 08/17/2026
Early initiation of insulin within two hours for moderate hyperglycemia in ICU patients significantly lowers 30-day mortality compared to delayed or no insulin therapy. This target trial emulation highlights the potential clinical benefit of prompt insulin treatment timing in critical care.
Read More
Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk
Posted inDiabetes & Endocrinology news Ophthalmology

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

Posted by By MedXY 05/03/2026
A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Early Controlled Mobilisation in Radial Head Fractures Enhances Recovery Without Clinically Significant Differences
  • Innovative Polyurethane Resin Cement with Dual Antibacterial Mechanisms for Enhanced Secondary Caries Prevention
  • Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials
  • The Community Pediatrics & Advocacy Curriculum: Standardizing Advocacy Education in Pediatric Graduate Medical Education
  • Sustained Remission and Long-Term Success: A Decade of Treat-to-Target Therapy in Early Rheumatoid Arthritis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top